Cargando…

ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy

The distribution and abundance of immune cells, particularly T‐cell subsets, play pivotal roles in cancer immunology and therapy. T cells have many subsets with specific function and current methods are limited in estimating them, thus, a method for predicting comprehensive T‐cell subsets is urgentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Ya‐Ru, Zhang, Qiong, Lei, Qian, Luo, Mei, Xie, Gui‐Yan, Wang, Hongxiang, Guo, An‐Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Full Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141005/ https://www.ncbi.nlm.nih.gov/pubmed/32274301 http://dx.doi.org/10.1002/advs.201902880

Ejemplares similares

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

IMMU-12. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS
por: Wilson, Zach, et al.
Publicado: (2023)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

IMMUNOPOTENTIATION BY IMMU 21 IN IMMUNOCOMPROMISED RATS
por: Chatterjee, S., et al.
Publicado: (1997)

ImmuCo: a database of gene co-expression in immune cells
por: Wang, Pingzhang, et al.
Publicado: (2014)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
por: Mishra, Deepak, et al.
Publicado: (2023)

IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
por: Pauneto, Coral Alicea, et al.
Publicado: (2023)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
por: Thompson, Eric, et al.
Publicado: (2023)

ImmuSort, a database on gene plasticity and electronic sorting for immune cells
por: Wang, Pingzhang, et al.
Publicado: (2015)

IMMU-20. Effective CAR-T cell medulloblastoma therapy in an immunocompetent mouse model
por: Tsahouridis, Rania, et al.
Publicado: (2022)

sc-ImmuCC: hierarchical annotation for immune cell types in single-cell RNA-seq
por: Jiang, Ying, et al.
Publicado: (2023)

IMMU-07. “STROKE MIMICS” ARE NOT BENIGN IN IMMUNOCOMPROMISED CHILDREN
por: Mahdi, Jasia, et al.
Publicado: (2021)

Corrigendum: ImmuSort, a database on gene plasticity and electronic sorting for immune cells
por: Wang, Pingzhang, et al.
Publicado: (2016)

A unique B2 B cell subset in the intestine
por: Shimomura, Yasuyo, et al.
Publicado: (2008)

γδ T cells: origin and fate, subsets, diseases and immunotherapy
por: Hu, Yi, et al.
Publicado: (2023)

EFFECT OF IMMUE-21 ON MURINE PERITONEAL MACROPHAGES AND SPLENIC LYMPHOCYTES
por: Chatterjee, S., et al.
Publicado: (1996)

Serial ImmuKnow assay in stable kidney transplant recipients
por: Moon, Hyung Hwan, et al.
Publicado: (2014)

Visible and subvisible particles in the BCG immunotherapeutic product ImmuCyst(®)
por: Kirkitadze, Marina, et al.
Publicado: (2016)

IMMU-03. CHARACTERIZING THE IMMUNE MICROENVIRONMENT OF PEDIATRIC BRAIN TUMORS
por: Galvin, Robert, et al.
Publicado: (2021)

IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022)

IMMU-10. TUMOR ASSOCIATED MYELOID CELLS DRIVE THE IMMUNOBIOLOGY OF HIGH RISK PEDIATRIC EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2022)

IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas
por: Labiano, Sara, et al.
Publicado: (2022)

IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
por: Fanuzzi, Mia, et al.
Publicado: (2023)

A Subset of Osteosarcoma Bears Markers of CXCL12‐Abundant Reticular Cells
por: Sosa, Branden R, et al.
Publicado: (2022)

A Subset of Nuclear Receptors are Uniquely Expressed in Uveal Melanoma Cells
por: Huffman, Kenneth Edward, et al.
Publicado: (2015)

A Unique Expression of Keratin 14 in a Subset of Trophoblast Cells
por: Abou-Kheir, Wassim, et al.
Publicado: (2015)

Aedes-AI: Neural network models of mosquito abundance
por: Kinney, Adrienne C., et al.
Publicado: (2021)

IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
por: Mahdi, Jasia, et al.
Publicado: (2023)

Improving reference standards for validation of AI-based radiography
por: Duggan, Gavin E, et al.
Publicado: (2021)

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
por: Golubovskaya, Vita, et al.
Publicado: (2016)

Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy
por: Lee, Derek, et al.
Publicado: (2022)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1naj8ngcp7tj06qquo6tmpb6hm